Eventide Healthcare & Life Sciences Fd Cl A
Eventide Healthcare & Life Sciences Fund Cl A (ETAHX)
Under typical market conditions, this fund commits a substantial portion—at least 80%—of its total investable capital (net assets plus any borrowed funds for investment) to equity and equity-linked instruments. These holdings specifically target companies within the healthcare and life sciences sectors, encompassing a range of securities such as common shares, preferred stock, options, and convertible debt. Furthermore, the fund possesses the flexibility to acquire stakes in companies domiciled outside the United States, without any geographical restrictions. This can be done either directly or through American Depositary Receipts (ADRs). Its investment mandate also allows for the inclusion of companies across the entire spectrum of market capitalizations, from small-cap to large-cap firms.
ETAHX Mutual Fund Chart & Stats
- Previous Close
- $51.29
- Sub-Category
- Sector-Specific
- Total Liabilities
- $19.97M
- Last Dividend Ex-Date
- Dec 16, 2021
- Expense Ratio
- 1.54%
- Holding Count
- 78
- Brand
- Mutual Fund Series Trust
- Dividend Yield
- (0.00%)
- Category
- Equity
- Total Assets
- 1.81B
- Shares Outstanding
- N/A
- 52-Week Range
- $44.12 - $63.85
ETAHX Mutual Fund News
Trevi Therapeutics: Buy Rating Reaffirmed as Chronic-Cough Pipeline Advances; $28 Price Target Unchanged
Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $28.00. Debanjana Chatterjee’s rating is based on several factors, including Trevi’s progress across
ETAHX Mutual Fund Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| GHGuardant Health | 5.37% |
| MIRMMirum Pharmaceuticals | 3.47% |
| KYMRKymera Therapeutics, Inc. | 3.22% |
| ABVXAbivax SA Sponsored ADR | 2.94% |
| USD_CASHBeLite Bio Inc | 2.83% |
| TRVITrevi Therapeutics | 2.77% |
| MBXMBX Biosciences, Inc. | 2.70% |
| PCVXVaxcyte, Inc. | 2.69% |
| CYTKCytokinetics | 2.69% |
| ARGXArgenx | 2.55% |
| Total | 31.23% |
Recently Viewed
No data currently available






